Form D · Biotechnology
Neumora Therapeutics, Inc.
Watertown, MA · CIK 0001885522
Offering snapshot reported Jan 3, 2023 · SEC filing
- Reported sold
- $474M Offering amount: $474M
- Investors reported
- 124 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 8, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 3, 2023 | Initial | $474,356,988 | No comparison | 124 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-469477
Source: Form D, filed Jan 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Berns | Director, Executive |
| Kristina Burow | Director |
| Matthew Fust | Director |
| Alaa Halawa | Director |
| Maykin Ho | Director |
| Robert Nelsen | Director |
| Joshua Pinto | Executive |
| Kari Stefansson | Director |
| Tamara Tompkins | Executive |
| Stacie Weninger | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
490 Arsenal Way, Suite 200
Watertown, MA, 02472
Watertown, MA, 02472